HOME > BUSINESS
BUSINESS
- FDA Approves Daiichi’s New ADC Datroway for Breast Cancer
January 21, 2025
- Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief
January 20, 2025
- Cell and Gene Therapy Market Expected to Top US$20 Billion by 2028: IQVIA
January 20, 2025
- Shionogi Reels in US$375 Million HHS Funding for Preventive COVID-19 Med
January 20, 2025
- Senju Files Mochida-Partnered Dry Eye Drug in Japan
January 20, 2025
- Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket
January 17, 2025
- Astellas to Offload Seroquel, “G1” LLP, to LTL Pharma
January 17, 2025
- J-TEC, Kobe Cell Therapy Player Form Capital Alliance
January 16, 2025
- Healios, Nobelpharma Reach No Deal on Cell Therapy MultiStem
January 16, 2025
- AnGes Partners with Stanford on Cancer Therapy Research
January 16, 2025
- Mochida to File Actemra Biosimilar in Japan
January 16, 2025
- ASKA/Veneno Tie Up for Discovery of Ion Channel Therapies
January 15, 2025
- Kyorin, Biodol Ink Option Deal for Novel Pain Drug
January 15, 2025
- Nippon Shinyaku Grabs Rights to Regenxbio’s MPS Gene Therapies
January 15, 2025
- Chugai to Transfer Tarceva to Cheplapharm in April
January 15, 2025
- Daiichi Buys IP Rights to Glycotope’s TA-MUC1 Antibody
January 15, 2025
- Daiichi’s Revised Filing for TROP2 ADC Accepted for FDA Review
January 15, 2025
- Ferring, Kissei Wind Up Desmopressin Collaboration
January 15, 2025
- FDA Accepts Leqembi SC for Review; Target Date Set to Aug. 31
January 15, 2025
- SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025
January 14, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
